Chloramphenicol

Overview

Chloramphenicol (Chloromycetin®, Viceton®) is a broad-spectrum antibacterial agent used in veterinary medicine for the treatment of serious bacterial infections in dogs and cats, particularly when other antimicrobial drugs are ineffective or inappropriate. It is known for its excellent tissue penetration, including therapeutic concentrations in the central nervous system, ocular tissues, and prostate.

Chloramphenicol acts primarily as a bacteriostatic antibiotic by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit of susceptible bacteria. At higher concentrations or against certain organisms, it may exhibit bactericidal activity.

Because of its high lipid solubility, chloramphenicol distributes widely throughout the body and reaches many tissues and body fluids. However, due to concerns regarding antimicrobial resistance and potential hematologic toxicity, systemic use is generally reserved for serious or life-threatening infections that are resistant to safer antimicrobial agents.

Chloramphenicol is metabolized primarily in the liver and eliminated mainly via the kidneys. Cats have a reduced capacity to metabolize the drug due to limited glucuronidation ability, resulting in a longer elimination half-life and a greater risk of adverse effects, particularly with prolonged therapy.

Indications

Chloramphenicol is used in dogs and cats for the treatment of serious bacterial infections caused by susceptible organisms, particularly when other antimicrobial agents are ineffective or inappropriate. Because of potential toxicity and concerns regarding antimicrobial resistance, its systemic use is generally reserved for infections that require deep tissue penetration or involve resistant pathogens.

• Serious bacterial infections resistant to other antibiotics: Chloramphenicol may be used for life-threatening infections caused by susceptible organisms when first-line antimicrobials are ineffective, including some methicillin-resistant staphylococcal infections.
• Central nervous system infections: Due to excellent penetration into cerebrospinal fluid, chloramphenicol may be used in the treatment of certain bacterial meningitis or CNS infections caused by susceptible organisms.
• Ocular infections: High lipid solubility allows good penetration into intraocular tissues, making chloramphenicol useful for some intraocular or deep ocular infections.
• Deep tissue infections: Effective tissue distribution allows use in infections involving difficult-to-reach sites such as the prostate and other well-perfused tissues.
• Infections caused by susceptible organisms: Includes bacteria such as Streptococcus, Staphylococcus, Salmonella, Haemophilus, Brucella, anaerobic bacteria (e.g., Clostridium and Bacteroides), and certain atypical pathogens including Chlamydia, Mycoplasma, and Rickettsia.

Dosage (Reference)

Dog

In dogs, chloramphenicol can be administered systemically or ophthalmically depending on the type and location of infection. Systemic dosing is typically required for deep infections or infections involving tissues such as the CNS or prostate.

Cat

Cats require lower systemic dosages of chloramphenicol because drug elimination is slower due to limited glucuronidation capacity. Careful monitoring is recommended, especially during prolonged treatment.

Warnings & Precautions

Chloramphenicol should be used cautiously in dogs and cats because of the potential for hematologic toxicity and drug accumulation in certain patients. Appropriate monitoring and careful patient selection are important when this drug is used systemically.

• Hematologic disorders: Use should be avoided or undertaken with extreme caution in animals with pre-existing bone marrow abnormalities (e.g., anemia or other hematologic disorders) because chloramphenicol may cause bone marrow suppression.
• Hepatic or renal impairment: Chloramphenicol is primarily metabolized in the liver and eliminated by the kidneys. Animals with hepatic or renal dysfunction may require dosage adjustments to prevent drug accumulation and toxicity.
• Cats: Cats are more sensitive to chloramphenicol toxicity because of reduced hepatic glucuronidation. Lower dosages are recommended and prolonged treatment should be approached cautiously.
• Neonates: Use with caution in neonatal animals, particularly young kittens, because immature metabolic pathways may result in drug accumulation and toxicity.
• Pregnancy and nursing: Chloramphenicol crosses the placenta and may affect fetal protein synthesis. It also enters milk; therefore, it should be used cautiously or avoided in pregnant or nursing animals whenever possible.
• Long-term therapy: When treatment is expected to continue for longer than about 14 days, periodic hematologic monitoring (CBC) should be considered to detect early signs of bone marrow suppression.
• Food animals: Use of chloramphenicol in food-producing animals is prohibited by regulatory authorities due to the risk of serious human toxicity.
• Occupational exposure: Chloramphenicol is classified as a hazardous drug; appropriate personal protective equipment (PPE) should be used during handling to minimize exposure.
• Drug name confusion: Care should be taken not to confuse chloramphenicol with other similarly named drugs such as chlorambucil, chlorpheniramine, or chlorpromazine.

Drug Interactions

Chloramphenicol can inhibit hepatic drug metabolism and may interact with several medications used in veterinary patients. Many of these interactions are related to inhibition of cytochrome P450 enzymes, which can increase the effects or toxicity of concurrently administered drugs.

• Acetaminophen: Concurrent use has been reported to increase serum concentrations of chloramphenicol in some human studies, although results are inconsistent. Veterinary data are limited.
• Aminoglycosides (e.g., amikacin, gentamicin, streptomycin): May result in antibacterial antagonism; the clinical significance of this interaction is uncertain.
• Beta-lactam antibiotics (e.g., penicillins, cephalosporins): Possible antibacterial antagonism when used together with chloramphenicol.
• Anti-anemia drugs (e.g., epoetin, folic acid, iron, vitamin B12): Chloramphenicol may delay the hematopoietic response to these medications.
• Aspirin and other salicylates: Chloramphenicol may delay hepatic metabolism of salicylates, potentially increasing the risk of toxicity.
• Cimetidine: May decrease chloramphenicol metabolism and increase the risk of drug accumulation and toxicity.
• Cyclophosphamide: Chloramphenicol may reduce formation of the active metabolite of cyclophosphamide and may also increase the risk of bone marrow suppression.
• Cyclosporine: Concurrent administration may increase cyclosporine concentrations and the risk of toxicity.
• Dipyrone: May increase the risk of bone marrow suppression when used with chloramphenicol.
• Glipizide: Chloramphenicol may reduce metabolism of sulfonylureas and increase the risk of hypoglycemia.
• Ketamine: Chloramphenicol may prolong anesthetic effects.
• Levamisole: Concurrent administration has been associated with fatalities and should be avoided.
• Lidocaine: Chloramphenicol may delay hepatic metabolism and prolong lidocaine effects.
• Methadone: Inhibition of hepatic metabolism may enhance and prolong methadone effects.
• Midazolam: Chloramphenicol may prolong sedative effects.
• Myelosuppressive drugs (e.g., azathioprine, interferons, methimazole, toceranib): Increased risk of additive bone marrow suppression.
• Opioids: Chloramphenicol may inhibit metabolism and prolong opioid effects.
• Pentobarbital: Chloramphenicol may markedly prolong anesthetic duration.
• Phenobarbital / Primidone: Chloramphenicol may inhibit phenobarbital metabolism, while phenobarbital may decrease chloramphenicol concentrations.
• Propofol: Chloramphenicol may prolong anesthetic effects.
• Rifampin: May decrease serum concentrations of chloramphenicol.
• Voriconazole: Chloramphenicol may increase serum concentrations of voriconazole.

Side Effects & Overdose

Side Effects

Chloramphenicol is generally well tolerated in adult dogs and cats when used at recommended doses, but adverse effects may occur, particularly with high doses or prolonged therapy. Cats may be more susceptible to toxicity because of slower drug metabolism.

• Gastrointestinal effects: The most commonly reported adverse effects include anorexia, vomiting, and diarrhea. These signs may occur during systemic treatment.
• Lethargy and neurologic signs: Some dogs may develop lethargy, shaking, or weakness. Peripheral neuropathy (hind limb weakness) has been reported, particularly in large-breed dogs.
• Bone marrow suppression: Dose-related, reversible bone marrow suppression may occur, especially with long-term therapy. Early signs may include neutropenia, lymphocytopenia, or decreased red blood cell production.
• Thrombocytopenia: Decreased platelet counts have been reported in cats receiving chloramphenicol therapy.
• Elevated liver enzymes: Mild increases in hepatic enzymes may occur in some dogs during treatment.
• Increased sensitivity in cats: Cats may develop adverse effects more readily due to slower drug metabolism, particularly when higher-than-recommended doses are used for prolonged periods.

Overdose

Large overdoses of chloramphenicol may increase the risk of serious hematologic toxicity. Management is primarily supportive and aimed at limiting further absorption and monitoring for complications.

• Bone marrow toxicity: Excessive doses may result in severe bone marrow suppression and hematologic abnormalities.
• Neurologic or systemic signs: High drug concentrations may lead to weakness, lethargy, or other systemic effects.
• Management: Treatment may include gastrointestinal decontamination if ingestion was recent, followed by supportive care and close monitoring of blood cell counts.
• Monitoring: CBC monitoring for several weeks may be required because bone marrow effects can develop after exposure.

Key Notes

Additional clinical considerations that may help guide appropriate use of chloramphenicol in dogs and cats in veterinary practice:

• Excellent tissue penetration: High lipid solubility allows chloramphenicol to achieve therapeutic concentrations in difficult-to-reach sites such as the eye, central nervous system, and prostate.
• Broad antimicrobial spectrum: Active against many gram-positive, gram-negative, and anaerobic bacteria as well as certain atypical organisms including Rickettsia, Chlamydia, and Mycoplasma.
• Primarily bacteriostatic activity: The drug usually inhibits bacterial growth rather than directly killing bacteria, although bactericidal activity may occur at higher concentrations against some pathogens.
• Resistance mechanisms: Bacterial resistance may develop through enzymatic inactivation (chloramphenicol acetyltransferase), efflux pumps, or altered ribosomal binding sites.
• Limited usefulness for lower urinary tract infections: Only a small proportion of the drug is excreted unchanged in the urine in dogs, making it less suitable for treating lower urinary tract infections.
• Bitter taste: Chloramphenicol tablets are extremely bitter, which may make administration difficult in some animals; giving the medication with food can help improve acceptance.